Lineage Cell Therapeutics Inc (LCTX)
1.74
-0.12 -6.45%
NYSE AM
Mar 5, 14:23
USD
View All Key Stats
Key Stats
Income Statement | |
Revenue (TTM) | 2.712M |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (TTM) | -0.18 |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Net Income (TTM) | -27.16M |
Profitability | |
Gross Profit Margin (Quarterly) | 82.14% |
Profit Margin (Quarterly) | -1.36K% |
Dividend | |
Dividend Yield (Forward) | Upgrade |
Dividend Yield | 0% |
Price and Valuation | |
Market Cap | 260.99M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
PS Ratio | 96.15 |
PE Ratio | -- |
Price to Book Value | 2.860 |
Other | |
Beta (5Y) | Upgrade |
Debt to Equity Ratio | 0.0057 |
Free Cash Flow (Quarterly) | -4.871M |
Return on Equity | Upgrade |
View All LCTX News
News
-
WireHeadlineTime (ET)
-
Yahoo03/04 12:30
-
Yahoo03/01 08:00
-
Yahoo02/23 08:00
-
SA Breaking News02/19 15:15
-
Yahoo02/16 08:00
-
SA Breaking News02/09 09:30
-
MT Newswires02/08 10:56
-
Yahoo02/08 08:00
-
Yahoo01/25 03:23
-
Yahoo01/21 08:05
-
Yahoo01/21 08:00
-
SA Breaking News01/21 07:19
-
MT Newswires01/21 06:18
-
Yahoo01/20 16:18
-
PR Newswire01/20 08:31
-
Yahoo01/20 08:24
-
SA Breaking News01/20 08:23
-
Yahoo12/28 08:00
-
Yahoo12/14 08:44
-
Yahoo12/09 08:00
View All Events
Events
Date | Type | Description |
---|---|---|
03/11/2021 | Earnings | Lineage Cell Therapeutics Inc Fourth Quarter Earnings Result for 2020 |
03/11/2021 16:30 EST | Misc | Lineage Cell Therapeutics Inc Fourth Quarter Earnings Conference Call for 2020 |
11/04/2020 | Earnings | Lineage Cell Therapeutics Inc Third Quarter Earnings Result for 2020 |
11/04/2020 16:30 EST | Misc | Lineage Cell Therapeutics Inc Third Quarter Earnings Conference Call for 2020 |
09/22/2020 07:30 PDT | Misc | Lineage Cell Therapeutics Inc Annual General Meeting for 2019 |
08/06/2020 17:30 EDT | Misc | Lineage Cell Therapeutics Inc Second Quarter Earnings Conference Call for 2020 |
08/06/2020 | Earnings | Lineage Cell Therapeutics Inc Second Quarter Earnings Result for 2020 |
05/07/2020 16:30 EDT | Misc | Lineage Cell Therapeutics Inc First Quarter Earnings Conference Call for 2020 |
05/07/2020 | Earnings | Lineage Cell Therapeutics Inc First Quarter Earnings Result for 2020 |
03/12/2020 16:30 EDT | Misc | Lineage Cell Therapeutics Inc Fourth Quarter Earnings Conference Call for 2019 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.lineagecell.com
- Investor Relations URL: http://investor.biotimeinc.com/phoenix.zhtml?c=83805&p=irol-IRHome
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Blend
- Next Earnings Release: Mar. 11, 2021
- Last Earnings Release: Nov. 04, 2020
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.
Analyst Coverage
Consensus Recommendations | |
Buy Recommendations | Upgrade |
Outperform Recommendations | Upgrade |
Hold Recommendations | Upgrade |
Underperform Recommendations | Upgrade |
Sell Recommendations | Upgrade |
Consensus Recommendation | Upgrade |
Consensus Rating | Upgrade |
Target Price | |
Price | 1.74 |
Price Target | Upgrade |
Price Target Upside (Daily) | Upgrade |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- LCTX Tweets Stocktwits
Advertisement